Oops! This Content is Members Only
The content you’re trying to view is for members only. Please register in order to access this content.
Registered users, please login to access this content.
- FDA Accepts for Priority Review Bristol Myers Squibb and bluebird bio Application for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121)
- FDA Approves Selinexor for Heavily Treated RRMM Patients
- Video Highlights from ASCO and EHA 2019
- World Myeloma Forum being rebranded as Myeloma360
- Phase 3 OPTIMISMM Trial Demonstrates Improved Progression-Free Survival
- Poseida Therapeutics Receives FDA Orphan Drug Designation For P-BCMA-101 For The Treatment Of Multiple Myeloma
- Cellectar Receives FDA Fast Track Designation for CLR 131 in Relapsed or Refractory Multiple Myeloma
- Overview of Key Early-phase CAR T-cell Therapy Studies in Relapsed or Refractory Multiple Myeloma
- What Are Chimeric Antigen Receptor (CAR) T-cells and What is Their Potential Target Site in Multiple Myeloma?
- Medicare to raise reimbursement for CAR-T cell therapies
Genmab Shares Drop On Legal Battle With J&J Over Cancer Drug
U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb and bluebird bio Application for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121)
As Myeloma Options Increase, So Do Challenges
GSK Highlights Scientific Advances Across Its Growing Oncology Portfolio At ESMO Virtual Congress 2020
SpringWorks Therapeutics Announces Clinical Collaboration with Janssen to Evaluate Nirogacestat in Combination with Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma
Takeda Announces Results from Phase 3 Clinical Trial Evaluating NINLARO™ (ixazomib) in Newly Diagnosed Multiple Myeloma